Newron Pharmaceuticals (NWPHF) News Today $20.00 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share News and Trends Stock AnalysisChartNews and TrendsShort Interest Newron Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Analysts Conflicted on These Healthcare Names: Newron Pharmaceuticals SpA (OtherNWPHF) and CSL (OtherCMXHF)October 23 at 5:32 PM | theglobeandmail.comNewron Pharmaceuticals S.p.A consensus price target decreased by 15.16% to CHF 34.25October 23 at 1:28 AM | msn.comAverage price target for Newron Pharmaceuticals S.p.A lowered by 14.23% to 36.91 €October 22 at 3:26 PM | msn.comNewron Pharmaceuticals S.p.A. Completes Enrollment In Pivotal Phase 3 ENIGMA-TRS 1 StudyOctober 22 at 3:26 PM | marketscreener.comMEQS-News: Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 StudyOctober 22 at 3:41 AM | markets.ft.comNewron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia TranscriptOctober 8, 2026 | seekingalpha.comUS FDA cites 4 deaths in Newron's schizophrenia drug trial holdOctober 8, 2026 | msn.comUS FDA flags four deaths in Newron's schizophrenia drug studiesOctober 8, 2026 | msn.comAnalysts Conflicted on These Healthcare Names: CSL (OtherCMXHF) and Newron Pharmaceuticals SpA (OtherNWPHF)October 8, 2026 | theglobeandmail.comNewron Pharmaceuticals S.p.A consensus price target lowered by 10.55% to CHF 40.37October 2, 2026 | msn.comUS FDA Maintains Clinical Hold on Patient Enrollment for Newron's Phase 3 Trial of Schizophrenia DrugSeptember 28, 2026 | marketscreener.comMFDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia StudySeptember 27, 2026 | rttnews.comNewron Pharmaceuticals S.p.A. gibt Update zur Phase-3-Studie ENIGMA-TRS 2 mit EvenamideSeptember 25, 2026 | de.marketscreener.comDNewron Pharmaceuticals S.P.A. Provides Update on Phase 3 Enigma-Trs 2 Study with EvenamideSeptember 25, 2026 | marketscreener.comMEQS-News: Newron presents H1 2026 results and provides corporate updateSeptember 23, 2026 | markets.ft.comNewron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2026September 22, 2026 | marketscreener.comMNewron Pharmaceuticals S p A : presents H1 2026 results and provides corporate updateSeptember 22, 2026 | marketscreener.comMEQS-News: Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide programSeptember 8, 2026 | markets.ft.comNewron Pharmaceuticals to Participate in June Investor ConferencesMay 28, 2026 | businesswire.comPatient death puts Newron’s late-stage schizophrenia trial on iceApril 30, 2026 | yahoo.comNewron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 StudyApril 29, 2026 | finance.yahoo.comNewron Announces AGM 2026 ResultsApril 23, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's EstimatesMarch 29, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 27, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call TranscriptMarch 24, 2026 | seekingalpha.comNewron Presents 2025 Financial Results and Provides 2026 OutlookMarch 24, 2026 | finance.yahoo.comNewron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)March 20, 2026 | businesswire.comNewron Announces Nominations to Its Board of Directors at Upcoming Annual General MeetingMarch 18, 2026 | tmcnet.comNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug EvenamideFebruary 17, 2026 | theglobeandmail.comNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia DrugFebruary 17, 2026 | theglobeandmail.comNewron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in SchizophreniaFebruary 3, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A.: Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter PatentJanuary 6, 2026 | finanznachrichten.deNewron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter PatentJanuary 6, 2026 | finance.yahoo.comNewron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference WeekDecember 22, 2025 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their Newron Pharmaceuticals S.p.A. (VTX:NWRN) OutlookDecember 16, 2025 | uk.finance.yahoo.comNewron Pharma initiated with a buy at Lucid CapitalDecember 11, 2025 | msn.comNewron Pharmaceuticals (SWX:NWRN): Valuation Check After ENIGMA TRS 2 Phase III Trial Kick-Off in the USDecember 11, 2025 | finance.yahoo.comNewron Pharma initiated with a buy at HC WainwrightDecember 8, 2025 | msn.comNewron Pharmaceuticals’ Phase III Study on Evenamide: A Potential Game-Changer for Treatment-Resistant SchizophreniaOctober 28, 2025 | msn.comNewron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of ...October 2, 2025 | finance.yahoo.comNewron Pharmaceuticals Launches Phase III Study for Schizophrenia TreatmentAugust 12, 2025 | msn.comNewron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)August 12, 2025 | finance.yahoo.comNewron Pharmaceuticals S.p.A. Just Missed EPS By 53%: Here's What Analysts Think Will Happen NextApril 5, 2025 | finance.yahoo.comEQS-News: Newron presents 2024 financial results and provides 2025 outlookApril 1, 2025 | markets.businessinsider.comNewron Pharmaceuticals S.p.A.: Newron Presents 2024 Financial Results and Provides 2025 OutlookApril 1, 2025 | finanznachrichten.deNewron Presents 2024 Financial Results and Provides 2025 OutlookApril 1, 2025 | finance.yahoo.comNewron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent ChairmanMarch 24, 2025 | uk.finance.yahoo.comEQS-News: Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent ChairmanMarch 24, 2025 | markets.businessinsider.comThose who invested in Newron Pharmaceuticals (VTX:NWRN) three years ago are up 548%March 17, 2025 | finance.yahoo.comNewron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH ConferenceMarch 11, 2025 | businesswire.com Newron Pharmaceuticals Media Mentions By Week Newron Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NWPHF News Sentiment▼-0.050.46▲Average Healthcare News Sentiment Newron Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NWPHF Articles This Week▼50▲NWPHF Articles Average Week Newron Pharmaceuticals Trends on MarketBeatThis week vs. last weekPage Views165-18% Get Newron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Rapport Therapeutics News Today GH Research News Today Cronos Group News Today Amphastar Pharmaceuticals News Today LB Pharmaceuticals News Today Avalyn Pharma News Today Harrow News Today Glass House Brands News Today Seaport Therapeutics News Today Theravance Biopharma News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Newron Pharmaceuticals dated 10/23/2026. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Newron Pharmaceuticals S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Newron Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
